Novo Nordisk × OpenAI — AI Across Drug Discovery to Commercial Operations

Novo Nordisk announced a strategic partnership with OpenAI to integrate advanced AI across the entire business — from drug discovery to commercial operations. Covers analysis of complex datasets, identifying drug candidates, manufacturing, supply chain and corporate functions. Pilot programmes launching in 2026, full integration by end of year. Strict data governance and human oversight built in.